EU Approves Lecanemab for Early Alzheimer’s Treatment
The European Medicines Agency (EMA) has granted its first approval for a treatment targeting the underlying processes of Alzheimer’s disease. The antibody Lecanemab is authorized for individuals with mild cognitive impairment or early-stage dementia. Produced by Biogen’s Swiss branch, this…